New data demonstrate the IL-22 AND-Body™ therapeutic, AMP-220, selectively targets gut tissue, conferring improved therapeutic efficacy and tolerability in vivo IND-enabling studies for AMP-220 are ongoing April 20, 2026 -- Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced new preclinical data for AMP-220, a gut-targeted IL-22 AND-Body™ therapeutic. The data wer

ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer, accounting for 10-15% of all lung cancer diagnoses [3]-[6] Lung cancer is the leading cause of cancer death in Australia and among men in Singapore, and the second highest among Singaporean women [7]-[9] April 20, 20

While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as a preprint, spotlights the fierce competition between Lilly and Novo in the weight loss drug market. Both companies have been trying to edge the other out by showcasing value-added drug features as well as investing in next-generation approaches and advancing oral formulations.

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities April 13, 2026 -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, cont

NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enst

Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing tr

Rapid Medical™, a leading developer of active endovascular devices, today announced U.S. FDA clearance of the TIGERTRIEVER™ 25, the latest addition to its TIGERTRIEVER platform, along with the first clinical cases demonstrating its performance in treating large vessel occlusion (LVO) stroke. Designed specifically for large clot burden in proximal vessels, TIGERTRIEVER 25 combines a 53 mm capture length with proprietary real-time force control. This capability, unique to the TIGERTRIEVER platform

AbbVie presented Phase II results for mirvetuximab soravtansine (Elahere) in folate receptor alpha (FRα)-positive, recurrent platinum-sensitive ovarian cancer at the SGO 2026 Annual Meeting. The open-label IMGN853-0420 trial reported a confirmed objective response rate of 62.7% (95% CI, 52.6–72.1) in the primary FRα ≥50% subgroup after six cycles of combination induction therapy, the company said. The 125-patient trial enrolled adults with FRα-positive recurrent platinum-sensitive high-grade ep

April 13, 2026 -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI). The Phase 1 randomized, double-blind, placebo-controlled, sing